Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Pfizer (PFE) PT Raised to $34 at Goldman Sachs
July 31, 2024 5:20 AM EDTGoldman Sachs analyst Chris Shibutani raised the price target on Pfizer (NYSE: PFE) to $34.00 (from $31.00) while maintaining a Buy rating.
The analyst comments "Relative outperformance on the day (+2% vs. flat XLV) appears warranted in our view given solid 2Q results... More
Pfizer hikes full-year outlook as Q2 results top estimates; shares up
July 30, 2024 6:58 AM EDT(Updated - July 30, 2024 9:48 AM EDT)
Pfizer (NYSE: PFE) shares rose more than 1% at the start of trading on Tuesday after the drugmaker hiked full-year guidance and reported better-than-expected Q2 earnings and revenue.
The companys earnings per share (EPS) in the second quarter stood at $0.60, surpassing the consensus estimate of $0.46. Revenue came in at $13.3 billion, also above the projected $13.03 billion.
Pfizer reported adjusted research and development expenses of $2.67 billion for the... More
